Drug Profile
Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences
Alternative Names: GEN-002; HSV-2 prophylactic (Px) vaccine - Genocea Biosciences; HSV-2 Px; ICP4383-766 + gD2; ICP4383-766 + TMR341-363; ICP4383-766 and gD2Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center; Genocea Biosciences; University of Washington
- Developer Genocea Biosciences
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus type 2 infections
Most Recent Events
- 20 May 2022 Discontinued - Preclinical for Herpes simplex virus type 2 infections (Prevention) in USA (Parenteral) (Genocea Biosciences pipeline, March 2023)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Parenteral)
- 01 Mar 2019 Preclinical development is ongoing in USA